ARTICE

Phase 2Biologic

AArtcline GmbH

ARTICE is one of 27 biologic programs targeting Septic Shock. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Septic ShockPhase 2

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

Primaxin

Pfizer

Preclinical

2 2

Intropin

Pfizer

Preclinical

2 3

Zyvox

Pfizer

Preclinical

1 4

Doribax

Spravato

2 6

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Coly-Mycin M

PParkedale

Preclinical

1 9

Tygacil

PPrism Pharmaceuticals

Preclinical

1 10

Glucocorticoid

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Septic Shock1 trial

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Recruiting·AArtcline GmbH·Phase 2·NCT05442710·142 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARTICE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARTICE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARTICE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Artcline GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AArtcline GmbH

ARTICE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Septic Shock1 trial

References

Drug Info

Quick Facts

Related News